Perspectives on renal bone disease

Kidney International

Volumn 70, Issue SUPPL. 104, 2006, Pages

  Goodman, W G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL DERIVATIVE; PARICALCITOL; PHOSPHATE BINDING AGENT;

BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; FRACTURE; HEMODIALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RISK; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

EID: 33751104446     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001980     Document Type: Article

References (58)

1. Goodman WG, Coburn JW, Slatopolsky E et al. Renal osteodystrophy in adult and pediatric patients. In: Favus M (eds). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th edn, American Society of Bone and Mineral Research: Washington, DC, 2003 pp. 430-447.
2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
3. Chen RA, Goodman WG. The role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004; 286: F1005-F1011.
4. De Francisco AM, Ellis HA, Owen JP et al. Parathyroidectomy in chronic renal failure. Q J Med (New Series) 1985; 55: 289-315.
5. Malberti F, Corradi B, Cosci P et al. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996; 28: 704-712.
6. Imanishi Y, Hosokawa Y, Yoshimoto K et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001; 107: 1093-1102.
7. Sherrard DJ, Hercz G, Pei Y, Segre G. The aplastic form of renal osteodystrophy. Nephrol Dial Transplant 1996; 11(Suppl 3): 29-31.
8. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
9. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int 1993; 44: 860-866.
10. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
11. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.
12. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
13. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-1201.
14. Weinstein RS. True strength. J Bone Miner Res 2000; 15: 621-625.
15. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502.
16. De Boer IH, Gorodetskaya I, Young B, Hsu CY et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769.
17. Hamdy NA, Kanis JA, Beneton MNC et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363.
18. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9.
19. Rix M, Andreassen H, Eskildsen P et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093.
20. Malberti F, Marcelli D, Conte F et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12: 1242-1248.
21. Kestenbaum B, Seliger SL, Gillen DL et al. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 2004; 65: 282-288.
22. Chertow GM, Plone M, Dillon MA et al. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295-300.
23. Goodman WG, Coburn JW, Slatopolsky E, Salusky IB. Renal osteodystrophy in adults and children, chap. 69. In: Favus MJ (eds). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th edn, Lippincott, Williams and Wilkins: Philadelphia, 1999 pp. 347-363.
24. Parfitt AM. A structural approach to renal bone disease. J Bone Miner Res 1998; 13: 1213-1220.
25. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387-403.
26. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
27. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201.
28. Coburn JW, Salusky IB, Norris KC, Goodman WG. Oral and parenteral calcitriol for the management of end-stage renal disease. Contrib Nephrol 1991; 90: 166-182.
29. Goodman WG. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Curr Opin Nephrol Hypertens 2005; 14: 355-360.
30. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25- dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143.
31. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-α-25- dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432.
32. Frazao JM, Elangovan L, Maung HM et al. Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36: 562-565.
33. Maung HM, Elangovan L, Frazao JM et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532-543.
34. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992; 19: 532-539.
35. Dressler R, Laut J, Lynn RI, Ginsberg N. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 1995; 43: 324-331.
36. Lindberg J, Martin KJ, Gonzalez EA et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323.
37. Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16: 210-218.
38. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236.
39. Szabo A, Merke J, Beier E et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056.
40. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94: 9831-9835.
41. Li YC, Amling M, Pirro AE et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-4396.
42. Ho C, Conner DA, Pollak MR et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995; 11: 389-394.
43. Tu Q, Pi M, Karsenty G et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 2003; 111: 1029-1037.
44. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-876.
45. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583.
46. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193.
47. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
48. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977-2983.
49. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476.
50. Sherrard DJ, Ott SM, Maloney NA et al. Uremic osteodystrophy: classification, cause and treatment. In: Frame B, Potts J (eds) Clinical Disorders of Bone and Mineral Metabolism. Excerpta Medica: Amsterdam, 1983 pp. 254-259.
51. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 2001; 12: 1978-1985.
52. Salusky IB, Ramirez JA, Oppenheim WL et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253-258.
53. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166.
54. Hendy GN, Hruska KA, Mathew S, Goltzman D. New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int 2006; 69: 218-223.
55. Lund RJ, Davies MR, Mathew S, Hruska KA. New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Metab 2006; 24: 169-171.
56. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510.
57. Mawad HW, Sawaya BP, Sarin R, Malluche HH. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 1999; 52: 160-166.
58. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.